Tag: Biotechnology Research

City Therapeutics, Inc.
United States

City Therapeutics Appoints Andy Orth as Chief Executive Officer

Orth brings more than 25 years of global industry experience to CEO role, with strong track record in corporate and commercial strategy City co-founder Dr. John Maraganore to retain active executive chair role to ensure company leads next-generation RNAi therapeutics CAMBRIDGE, Mass – City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced the appointment of Andrew “Andy” Orth … Continue reading City Therapeutics Appoints Andy Orth as Chief Executive Officer

Impact Newswire
Maurice van Tilburg
Europe

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization Los Angeles and Amsterdam – December 30, 2024 – Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced Chairman of the Board, Maurice van Tilburg, has been appointed as Chief Executive Officer of its subsidiary GEDi Cube BV (a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies) DBA RenovaroCube. … Continue reading Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Impact Newswire
Cure Rare Disease
United States

Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer

Press Release – December 18, 2024 – WOODBRIDGE, Conn. – Cure Rare Disease, a nonprofit biotechnology organization dedicated to advancing treatments for neglected rare and genetic diseases, is proud to announce Brittany Stineman as its new Chief Advancement Officer, effective January 2025. “Brittany’s story is a testament to the power of hope, resilience, and action” Post this As a mother who faced the unimaginable journey … Continue reading Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer

Impact Newswire
Adicet Bio
United States

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Press Release – December 18, 2024 – REDWOOD CITY, Calif. & BOSTON – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie … Continue reading Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Impact Newswire
Neophore
Untied Kingdom

Neophore appoints Michael Shih as Chief Executive Officer

NeoPhore appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international pharma and biotech deal-making• New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer Press Release – London UK, 16 December 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as … Continue reading Neophore appoints Michael Shih as Chief Executive Officer

Impact Newswire
incardatherapeutics
United States

InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO

Press Release – NEWARK, Calif. – December 10, 2024 – InCarda Therapeutics, a clinical stage biopharmaceutical company developing novel therapeutics for cardiac arrythmias, has announced that Myles Greenberg, MD, MBA will serve as its new president and CEO. Dr. Greenberg joins the company as it advances clinical development of its lead product, an orally inhaled treatment for the rapid conversion of recent-onset and symptomatic atrial fibrillation (AF) to sinus … Continue reading InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO

Impact Newswire
Biotangents
Untied Kingdom

Biotangents Set to Revolutionise Dairy Farming Industry as Investment Round Announced

Press Release – November 28, 2024 – EDINBURGH, Scotland – Technology developed by Scottish biotech Biotangents, which has announced its latest investment round, is set to revolutionise the dairy farming industry with the world’s fastest on-farm, point-of-care diagnostic device aimed at addressing disease in dairy cows. Bovine mastitis alone is estimated to cost the global dairy farming industry around £20 billion every year, costing the average … Continue reading Biotangents Set to Revolutionise Dairy Farming Industry as Investment Round Announced

Impact Newswire
SOPHiA GENETICS
Europe

SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

Press Release – 11/21/2024 Leading community-based practice to utilize increased set of solid tumor applications Boston, MA and Rolle, Switzerland, November 21, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has … Continue reading SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

Impact Newswire
Eikon Therapeutics
United States

Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer

Press Release – November 20, 2024 – HAYWARD, Calif. – Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that Michael A. Klobuchar has been appointed Chief Operating Officer. He joins Eikon from Merck & Co. Inc. where he most recently served as Executive Vice President and Chief Strategy Officer. “Mike is an outstanding leader … Continue reading Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer

Impact Newswire